ISSN:
1432-2072
Keywords:
Clozapine
;
Schizophrenia
;
Tardive dyskinesia
;
Parkinsonism
;
Neutropenia
;
Convulsions
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Clozapine, which has had limited clinical testing in the U.S.A., was evaluated in 12 chronic schizophrenic patients with tardive dyskinesia. Its antipsychotic activity was again demonstrated and it suppressed the symptoms of tardive dyskinesia with a marked rebound occurring in these symptoms when it was withdrawn; there was no rigidity or other Parkinsonian symptoms. However, out of a total of 12 patients, neutropenia (800 and 1120) occurred in two patients, convulsions in one patient, marked withdrawal effects in three patients, and a hypotensive collapse with atrial fibrillation in one patient. If these adverse effects are confirmed in a larger sample size, then despite the novel desirable effects of clozapine it would seem unlikely that it will gain widespread or routine use1.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00571412
Permalink
